Celecoxib or Naproxen Treatment Does Not Benefit Depressive Symptoms in Persons Age 70 and Older: Findings From a Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Background Several lines of evidence suggest that inflammatory mechanisms may be involved in the severity and progression of depression. One pathway implicated is the production of prostaglandins via the enzyme cyclooxygenase (COX). Although late-life depression in particular has been associated with inflammation, we know of no published studies using COX inhibitors, such as nonsteroidal anti-inflammatory drugs (NSAIDs), in the treatment of depressive syndromes in this population. Objective To evaluate the effect of the NSAIDs celecoxib and naproxen on depressive symptoms in older adults. Methods The Alzheimer's Disease Anti-inflammatory Prevention Trial was a randomized, placebo-controlled, double-masked clinical trial conducted at six U.S. memory clinics. Cognitively normal volunteers age 70 and older with a family history of Alzheimer-like dementia were randomly assigned to receive celecoxib 200 mg twice daily, naproxen sodium 220 mg twice daily, or placebo. The 30-item version of the Geriatric Depression Scale (GDS) was administered to all participants at enrollment and at yearly follow-up visits. Participants with a GDS score greater than 5 at baseline were classified as depressed. Results Of 2,528 participants enrolled, 2,312 returned for at least one follow-up visit. Approximately one-fifth had significant depressive symptoms at baseline. Mean GDS score, and the percentage with significant depressive symptoms, remained similar over time across all three treatment groups. Furthermore, there was no treatment effect on GDS scores over time in the subgroup of participants with significant depressive symptoms at baseline. In longitudinal analysis using generalized estimating equations (GEE) regression, higher baseline GDS scores, a prior psychiatric history, older age, time in the study, and lower cognition interacting with time, but not treatment assignment, were associated with significantly higher GDS scores over time. Conclusion Treatment with celecoxib or naproxen did not improve depressive symptoms over time compared with placebo. While inflammation has been implicated in late-life depression, these results do not support the hypothesis that inhibition of the COX pathway with these NSAIDs at these doses alleviates depressive symptoms in older adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a large scale randomized controlled trial designed to evaluate NSAID treatment (celecoxib & naproxen) in approximately 2,500 elderly adults with late-life depression found no significant effect in reducing modified Geriatric Depression Scale (GDS) scores compared to placebo (Fields et al., 2012)”
From A Review of the Relationship between Proinflammatory Cytokines and Major Depressive Disorder (2014) · cites this paper as Fields et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
(1987) · PubMed · Cited by 2,657
Depression in Late Life: Review and Commentary
Blazer, D. G. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.3.m249 · Cited by 2,344
Alexopoulos, G. S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66665-2 · Cited by 2,024
Appendix G: Geriatric Depression Scale
(2015) · Deep Brain Stimulation Management · doi:10.1017/cbo9781316026625.021 · Cited by 1,536
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., & Schmidt, K. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0597 · Cited by 995
Cited by
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly
Wongrakpanich, S., Wongrakpanich, A., Melhado, K., & Rangaswami, J. (2018) · Aging and disease · doi:10.14336/ad.2017.0306 · Cited by 917
“[41] Fields C, Drye L, Vaidya V, Lyketsos C (2012).”
BackgroundKreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.155 · Cited by 663
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
“On the other hand; 12 month treatment with naproxen among 1,757 healthy users had no impact on depressive symptoms [43].”
BackgroundInfluentialKöhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432
“Two studies investigated healthy individuals, either individuals with a family history of Alzheimer-like dementia (33) or individuals with moderately increased low-density lipoprotein levels (49).”
BackgroundA Review of the Relationship between Proinflammatory Cytokines and Major Depressive Disorder
Young, J. J., Bruno, D., & Pomara, N. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.07.032 · Cited by 422
“Depression Scale (GDS) scores compared to placebo (Fields et al., 2012), suggesting that antiinflammatory monotherapy may be insufficient to produce significant antidepressant effects.”
BackgroundKopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279
“After the treatment with either drug, the GDS score was not reduced (Fields et al., 2012).”
BackgroundEvidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders
Gibney, S. M., & Drexhage, H. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9462-8 · Cited by 234
Krogh, J., Benros, M. E., Jørgensen, M. B., Vesterager, L., Elfving, B., & Nordentoft, M. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.08.014 · Cited by 185
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adzic, M., Brkic, Z., Mitic, M., Francija, E., Jovicic, M. J., Radulovic, J., & Maric, N. P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 156
“, it showed beneficial effects on depressive symptoms in patients with active osteoarthritis [127], but it did not improve depressive symptoms in healthy subjects [128].”
BackgroundTherapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far
Roman, M., & Irwin, M. R. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.09.016 · Cited by 132
“Furthermore, across all three treatment groups, there was no treatment effect on GDS scores in the significantly depressed patient subgroups (Fields et al., 2012).”
BackgroundInflammation‐driven brain and gut barrier dysfunction in stress and mood disorders
Doney, E., Cadoret, A., Dion‐Albert, L., Lebel, M., & Ménard, C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15239 · Cited by 151
“(Fields et al., 2012), explained by the effects of aging on multiple factors including immune responses, gut microbiome, and memory encoding (Martinez- Canabal et al., 2013).”
BackgroundA critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression
Eyre, H. A., Air, T., Proctor, S. J., Rositano, S., & Baune, B. T. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.10.003 · Cited by 132
Predictors of treatment outcome in depression in later life: A systematic review and meta-analysis
Tunvirachaisakul, C., Gould, R. L., Coulson, M., Ward, E. V., Reynolds, G., Gathercole, R. L., Grocott, H., Supasitthumrong, T., Tunvirachaisakul, A., Kimona, K., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.008 · Cited by 129
Evidence for Inflammation-Associated Depression
Liu, C. S., Adibfar, A., Herrmann, N., Gallagher, D., & Lanctôt, K. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_2 · Cited by 123
Anti-TNF-α Compounds as a Treatment for Depression
Uzzan, S., & Azab, A. N. (2021) · Molecules · doi:10.3390/molecules26082368 · Cited by 126
“Nevertheless, here too, studies published negative findings regarding the effectiveness of anti-inflammatory/immune-modulating medications as a treatment for mood disorders [124,125].”
Arabzadeh, S., Ameli, N., Zeinoddini, A., Rezaei, F., Farokhnia, M., Mohammadinejad, P., Ghaleiha, A., & Akhondzadeh, S. (2015) · Bipolar Disorders · doi:10.1111/bdi.12324 · Cited by 98
Sethi, R., Gómez‐Coronado, N., Walker, A. J., Robertson, O. D., Agustini, B., Berk, M., & Dodd, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00605 · Cited by 100
Modulating Neuroinflammation to Treat Neuropsychiatric Disorders
Radtke, F. A., Chapman, G., Hall, J., & Syed, Y. A. (2017) · BioMed Research International · doi:10.1155/2017/5071786 · Cited by 76
“However, there was no significant change in that percentage over the trial, or in scores of individual probands [184].”
BackgroundNovel Pharmacological Approaches to the Treatment of Depression
Elias, E., Zhang, A. Y., & Manners, M. T. (2022) · Life · doi:10.3390/life12020196 · Cited by 90
“Interestingly, neither aspirin nor naproxen produced antidepressant effects in elderly patients [215,216], indicating that there the limitations to this treatment that should be further defined.”
BackgroundInflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment
Schmidt, F. M., Kirkby, K. C., & Lichtblau, N. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160115130414 · Cited by 82
“However in a recent [75] and another large study, no antidepressant effects of celecoxib or naproxen monotherapy in elderly subjects were detected [76].”
ResultBrain-immune crosstalk in the treatment of major depressive disorder
Branchi, I., Poggini, S., Capuron, L., Benedetti, F., Poletti, S., Tamouza, R., Drexhage, H. A., Penninx, B. W. J. H., & Pariante, C. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.016 · Cited by 64
Mind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 72
“However, it should be noted that other trials have resulted in conflicting findings, with several showing no beneficial effect of celecoxib in depression (Musil et al., 2011; Fields et al., 2012).”
BackgroundResultMaes, M. H. J. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9326-6 · Cited by 59
The genetics of selective serotonin reuptake inhibitors
Kroeze, Y., Zhou, H., & Homberg, J. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.015 · Cited by 60
“For example, it is shown that cyclooxygenase inhibition – an enzyme that is responsible for formation of prostaglandins – is bene fi cial in treating depression (Guo et al., 2009; Abbasi et al., 2012), however there are also studies showing negative results (Fields et al., 2012).”
ResultDöme, P., Tombor, L., Lazáry, J., Gonda, X., & Rihmer, Z. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.12.015 · Cited by 53
“One longitudinal, large-scale, placebo-controlled trial found naproxen (another over-thecounter NSAID) to be ineffective in improving depressive symptoms over time in cognitively normal volunteers at risk of Alzheimer’s disease (Fields et al., 2012).”
Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?
Baune, B. T. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000140 · Cited by 47
“Although some studies have found positive antidepressant effects [66,70,72,73], others have found no effect [67,68,74] and yet others have found detrimental effects suggesting NSAIDs may reduce the antidepressant effect of selective serotonin reuptake inhibitors [69,75].”
ResultBaune, B. T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_19 · Cited by 50
“Importantly, only a few adults experience a full symptomatic and functional remission between depressive episodes with a high risk of long-term loss of function [75, 76].”
BackgroundAntidepressant psychopharmacology: is inflammation a future target?
Benedetti, F., Zanardi, R., & Mazza, M. G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000403 · Cited by 45
Alamdarsaravi, M., Ghajar, A., Noorbala, A.-A., Arbabi, M., Emami, A., Shahei, F., Mirzania, M., Jafarinia, M., Afarideh, M., & Akhondzadeh, S. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.05.029 · Cited by 43
“Nevertheless, this should be exclusively determined by long-term intervention studies (Fields et al., 2012; Nery et al., 2008).”
BackgroundResultInfluentialThe role of immunomodulators in treatment-resistant depression: case studies
Beckett, C. W., & Niklison-Chirou, M. V. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01147-6 · Cited by 45
“For example, the only long-term trial of Celecoxib monotherapy in depression conducted to date, found no treatment effect [57, 63].”
BackgroundYao, Y., Huang, H., Yang, Y., & Guo, J. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.12.047 · Cited by 43
“However, a recent study showed that COX-2 inhibitor does not improve depressive symptoms in persons aged 70 and over (Fields et al., 2012).”
BackgroundMohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015592215 · Cited by 39
Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression
Noto, C., Rizzo, L. B., Mansur, R. B., McIntyre, R. S., Maes, M., & Brietzke, E. (2014) · Neuroimmunomodulation · doi:10.1159/000356549 · Cited by 38
Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression
Businaro, R., Vauzour, D., Sarris, J. J., Münch, G. W., Gyengési, E., Brogelli, L., & Zuzarte, P. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.669846 · Cited by 45
Raison, C. L. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_26 · Cited by 36
Baldwin, D. S., Hou, R. H., Gordon, R., Huneke, N. T. M., & Garner, M. J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0423-2 · Cited by 41
Regulska, M., Szuster-Głuszczak, M., Trojan, E., Leśkiewicz, M., & Basta‐Kaim, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200807144530 · Cited by 67
Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders
Perrone, M. G., Centonze, A., Miciaccia, M., Ferorelli, S., & Scilimati, A. (2020) · Molecules · doi:10.3390/molecules25225388 · Cited by 35
Strekalova, T. V., Pavlov, D., Трофимов, А. Н., Anthony, D. C., Svistunov, A. A., Proshin, A. T., Umriukhin, A., Lyundup, A. V., Lesch, K., & Cespuglio, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042061 · Cited by 32
Gong, H., Su, W., Deng, S., Luo, J., Du, Z., Luo, Y., Lv, K., Zhu, D.-M., & Fan, X. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03317-3 · Cited by 34
“4, four studies with 6 comparisons and 2533 participants investigated the ef fi cacy of NSAIDs, including celecoxib [49, 55], naproxen [49, 55], ibuprofen [49], and aspirin [56, 57].”
How Predictive of Dementia are Peripheral Inflammatory Markers in the elderly?
Metti, A. L., & Cauley, J. A. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.68 · Cited by 32
Al‐Hakeim, H. K., Twayej, A. J., Al-Dujaili, A. H., & Maes, M. H. J. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200102100307 · Cited by 31
Kargar, M., Yousefi, A., Mojtahedzadeh, M., Akhondzadeh, S., Artounian, V., Abdollahi, A., Ahmadvand, A., & Ghaeli, P. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13880 · Cited by 32
Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Rahola, J. G. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604533 · Cited by 32
Forbes, M., O'Neil, A. E., Lane, M. M., Agustini, B., Myles, N., & Berk, M. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00858-2 · Cited by 28
“The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) found no difference between celecoxib, naproxen and placebo on the Geriatric Depression Scale out to 60 months [154].”
BackgroundSu, W., Hu, T., & Jiang, C. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809112028 · Cited by 29
“For example, the suggested dose of celecoxib is mostly 200 mg bid (400 mg/day) [130-133, 135, 140-142].”
BackgroundThe role of depression and neuroimmune axis in the prognosis of cancer patients.
Aldea, M. D., Craciun, L., Tomuleasa, C., & Crivii, C. B. (2014) · PubMed · Cited by 32
Berk, M., Agustini, B., Woods, R. L., Nelson, M. R., Shah, R. C., Reid, C. M., Storey, E., Fitzgerald, S. M., Lockery, J. E., Wolfe, R. S., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01020-5 · Cited by 28
Metti, A. L., Yaffe, K. S., Boudreau, R. M., Ganguli, M., López, O. L., Stone, K. L., & Cauley, J. A. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12739 · Cited by 25
Dogaru, I.-A., Puiu, M. G., Manea, M., & Dionisie, V. (2022) · Brain Sciences · doi:10.3390/brainsci12101403 · Cited by 23
Branchi, I., Viglione, A., Vai, B., Cirulli, F., Benedetti, F., & Poggini, S. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103923 · Cited by 19
“…anti-inflammatory drugs in treating depression (Bai et al., 2020; Kappelmann et al., 2018; Kohler et al., 2014; Yatham et al., 2019), others have reported no or even detrimental effects (Almeida et al., 2010; Fields et al., 2012; Fond et al., 2014; Fourrier et al., 2018; Wittenberg et al., 2019).”
The Role of Inflammation in Depression and Beyond: A Primer for Clinicians
Calagua-Bedoya, E. A., Rajasekaran, V., de Witte, L. D., & Pérez-Rodríguez, M. M. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01526-z · Cited by 20
“Nevertheless, celecoxib [109], naproxen [109] and etoricoxib [110] have also been correlated with a lack of antidepressant effect.”
Antidepressant Effects of NSAIDs in Rodent Models of Depression—A Systematic Review
Bay-Richter, C., & Wegener, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.909981 · Cited by 19
“On the contrary, Fields et al. (2012) found no effect of celecoxib or naproxen on depressive symptoms in persons above 70 years old.”
BackgroundWestwell-Roper, C. Y., & Stewart, S. E. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00264 · Cited by 18
Teixeira, A. L., Barbosa, I. G., Bauer, M. E., & de Miranda, A. S. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.10019 · Cited by 13
“However, in contrast with studies carried out in adult populations,clinicaltrialswithcelecoxib(Fields etal .,2012),naproxen (Fields et al ., 2012), and aspirin (Berk et al ., 2021) in LLD failed to demonstrate benefit of anti-inflammatory strategies.”
Wium‐Andersen, I. K., Wium‐Andersen, M. K., Jørgensen, M. B., & Osler, M. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.105 · Cited by 13
A Review on Inflammation and its Pharmacotherapy
Shinde, M. G., Sayyad, K. D., Swami, G. V., Savant, P. B., Yalmar, P. R., & Mane, S. T. (2023) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2023.00036 · Cited by 11
Shvartsur, R., Agam, G., Shnaider, A., Uzzan, S., Nassar, A., Jabarin, A., Abu‐Freha, N., Meir, K. S., & Azab, A. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111827 · Cited by 12
Treatment resistant depression in elderly
Wang, S.-C., Yokoyama, J. S., Tzeng, N., Tsai, C.-F., & Liu, M. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.004 · Cited by 14
Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders
Ballaz, S., & Bourin, M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_20 · Cited by 16
Shaikh, N. F., Shen, C., LeMasters, T., Dwibedi, N., Ladani, A. P., & Sambamoorthi, U. (2023) · Cancer Informatics · doi:10.1177/11769351231165161 · Cited by 10
“32 NSAIDs were found to be associated with lower depression scores in patients with OA.”
BackgroundWestwell-Roper, C. Y., Best, J. R., Elbe, D., MacFadden, M., Baer, S., Tucker, L., Au, A., Naqqash, Z., Lin, B., Lu, C., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054296 · Cited by 9
Effects of Dexamethasone and Pentoxifylline on Mania-like and Depression-like Behaviors in Rats
Nassar, A., & Azab, A. N. (2022) · Pharmaceuticals · doi:10.3390/ph15091063 · Cited by 8
“In contrast to these positive findings, contradicting results have also been reported [22].”
ResultSun, Y., Narayan, V. A., & Wittenberg, G. M. (2016) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0090-9 · Cited by 8
“COX 2 inhibitors such as celecoxib have been reported to benefit MDD patients when used together with other antidepressants but not when using alone [11, 13].”
BackgroundAnti-inflammatory Intervention in Depression—Reply
Köhler‐Forsberg, O., Benros, M. E., & Krogh, J. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3186 · Cited by 7
ROLE OF ENZYMES IN THE PATHOGENESIS OF DEPRESSION
Walia, V. (2016) · Journal of Critical Reviews · Cited by 11
Anti-Inflammatory Agents as Antidepressants: Truth or Dare
Raison, C. L., & Miller, A. H. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150501-08 · Cited by 5
Vaccination and Immunotherapy for Major Depression
Evrensel, A., Ünsalver, B. Ö., Ceylan, M. E., & Tarhan, N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_25 · Cited by 6
Shaikh, N. F., & Sambamoorthi, U. (2019) · Psychiatric Quarterly · doi:10.1007/s11126-019-09693-6 · Cited by 6
Inflammatory Abnormalities in Major Depressive Disorder
Singhal, G., & Baune, B. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00006-9 · Cited by 4
Brain FADE syndrome: the final common pathway of chronic inflammation in neurological disease
Hanafy, K. A., & Jovin, T. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332776 · Cited by 4
Immunoinflammatory Therapies in Psychiatry: Current Evidence Base
Menon, V., & Ameen, S. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_505_17 · Cited by 5
“, 2012([34]) Double-blind, randomizedthree”
BackgroundInfluentialAkóṣílè, W. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.210971 · Cited by 4
Efficacy of Anti-Inflammatory Treatment in Depression
Köhler‐Forsberg, O., & Benros, M. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00030-1 · Cited by 4
João, R. B., de Azevedo, J. P. R. P. T., Pereira, D. A., Ragazzo, P. C., & de Oliveira, P. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1577530 · Cited by 3
Rheumatoid Arthritis, Depression, and the Role of Celecoxib
Al-Baz, N., & Karim, M. A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00468-w · Cited by 2
Palladini, M., Azzalin, A. A., Bessi, M., LORENZO, R. D., Rovere, P. Q., Benedetti, F., & Mazza, M. G. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10247-w · Cited by 1
“…to antidepressants alone and placebo (Abbasi et al. 2012 ; Akhondzadeh et al. 2009 ; Elnazer et al. 2021 ; Muller et al. 2006 ), while incon - sistent findings were reported when investigating the effect of celecoxib monotherapy (Fields et al. 2012 ; Husain et al. 2020 ; Iyengar et al. 2013 ).”
Kotova, M. M., Kolesnikova, T. O., Amikishiev, S. V., Riga, V. D., de Abreu, M. S., Евгеньевич, М. П., & Kalueff, A. V. (2026) · Brain Sciences · doi:10.3390/brainsci16080815 · Cited by 1
Analgesics and anti-inflammatories
Teoh, L., Moses, G., & McCullough, M. J. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009057950.006 · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 2
Трофимов, А. Н. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240205at · Cited by 1
Brief geriatric depression scale as a measure of change in level of depression
Cheng, S., Yu, E. C. S., Chan, L. K., & Wong, M. M. L. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3965
“Self-report depression scales are often used as outcome measures in clinical trials for depression, one of which is the Geriatric Depression Scale (GDS; (Cheng et al., 2012; Fields et al., 2012).”
MethodKöhler‐Forsberg, O., & Gasse, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-32480-7_24 · Cited by 1
Is There Still Hope for Treating Depression With Antiinflammatories?
Baune, B. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00033-7 · Cited by 1
Future Perspectives on Immune-Related Treatments
Baune, B. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00035-0
Lithium – a Loneliness of an Efficacious Unpatented Drug
Azab, A. N. (2018) · Austin Journal of Psychiatry and Behavioral Sciences · doi:10.26420/austinjpsychiatrybehavsci.2018.1066
The two sides of the coin of psychosocial stress: evaluation by positron emission tomography
Feltes, P. K. (2018) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Nettis, M. A., & Mondelli, V. (2018) · PNEI REVIEW · doi:10.3280/pnei2018-002005
Baune, B. T. (2019) · Cambridge University Press eBooks · doi:10.1017/9781139839518.008
Limandri, B. J. (2020) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20191218-03
Depression in late life: Linking the immunometabolic dysregulation with clinical features
de la Torre‐Luque, A., & Ayuso‐Mateos, J. L. (2021) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsm.2021.06.004 · Cited by 1
Koga, M., Nakashima, H., Saito, M., Sato, M., Nakagawa, R., Sato, T., Asai, F., Ishii, T., Kinoshita, M., Nagamine, M., et al. (2026) · Journal of Neuroinflammation · doi:10.1101/2025.10.10.681580 · Cited by 1
Metadata
- Authors
- Fields, C., Drye, L., Vaidya, V., & Lyketsos, C.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Lyketsos, Constantine
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 20
- Issue
- 6
- Pages
- 505-513
- ISSN
- 1064-7481 (ISSN-L)
- PMC
- PMC3209494
- OpenAlex
- W2095272329
- Cited by
- 96
- References
- 56
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 9 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (U01AG015477, P50AG005146, U01-AG15477)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- celecoxib, naproxen, nonsteroidal anti-inflammatory drugs, geriatric depression, depressive symptoms, cyclooxygenase inhibition, inflammation, Alzheimer's disease prevention, Geriatric Depression Scale, cognitive decline
- MeSH terms
- Celecoxib, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Depression, Female, Humans, Longitudinal Studies, Male, Naproxen, Pyrazoles, Sulfonamides, Treatment Outcome, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.